Analysts forecast that Catalyst Biosciences Inc (NASDAQ:CBIO) will report earnings per share of ($1.20) for the current fiscal quarter, according to Zacks. Zero analysts have issued estimates for Catalyst Biosciences’ earnings. Catalyst Biosciences posted earnings of ($0.54) per share in the same quarter last year, which suggests a negative year-over-year growth rate of 122.2%. The firm is scheduled to report its next earnings report on Thursday, August 1st.
According to Zacks, analysts expect that Catalyst Biosciences will report full year earnings of ($4.88) per share for the current fiscal year. Zacks Investment Research’s earnings per share averages are an average based on a survey of sell-side research firms that cover Catalyst Biosciences.
Catalyst Biosciences (NASDAQ:CBIO) last announced its quarterly earnings results on Thursday, May 2nd. The biopharmaceutical company reported ($1.26) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.08) by ($0.18).
Separately, Zacks Investment Research downgraded shares of EXACT Sciences from a “hold” rating to a “sell” rating in a report on Tuesday, July 2nd.
Several hedge funds and other institutional investors have recently bought and sold shares of CBIO. Nantahala Capital Management LLC bought a new stake in shares of Catalyst Biosciences during the 4th quarter worth $6,748,000. Dimensional Fund Advisors LP lifted its holdings in shares of Catalyst Biosciences by 25.7% during the 4th quarter. Dimensional Fund Advisors LP now owns 508,232 shares of the biopharmaceutical company’s stock worth $4,010,000 after acquiring an additional 103,874 shares during the last quarter. Assenagon Asset Management S.A. lifted its holdings in shares of Catalyst Biosciences by 40.8% during the 1st quarter. Assenagon Asset Management S.A. now owns 288,600 shares of the biopharmaceutical company’s stock worth $2,341,000 after acquiring an additional 83,701 shares during the last quarter. Bank of America Corp DE lifted its holdings in shares of Catalyst Biosciences by 1,127.7% during the 4th quarter. Bank of America Corp DE now owns 58,559 shares of the biopharmaceutical company’s stock worth $462,000 after acquiring an additional 53,789 shares during the last quarter. Finally, BlackRock Inc. lifted its holdings in shares of Catalyst Biosciences by 4.8% during the 4th quarter. BlackRock Inc. now owns 846,529 shares of the biopharmaceutical company’s stock worth $6,680,000 after acquiring an additional 39,088 shares during the last quarter. 68.36% of the stock is owned by institutional investors.
NASDAQ:CBIO traded down $0.01 during trading hours on Friday, hitting $8.42. The stock had a trading volume of 710 shares, compared to its average volume of 348,757. The business’s 50 day moving average price is $7.81. The company has a debt-to-equity ratio of 0.02, a current ratio of 24.94 and a quick ratio of 24.94. Catalyst Biosciences has a one year low of $6.20 and a one year high of $13.36. The stock has a market cap of $103.15 million, a price-to-earnings ratio of -3.15 and a beta of 2.19.
Catalyst Biosciences Company Profile
Catalyst Biosciences, Inc, a clinical-stage biopharmaceutical company, focuses on developing medicines to address hematology indications. Its product pipeline includes marzeptacog alfa, a Factor VIIa variant that is in a Phase II/III clinical trial for the prophylactic treatment of individuals with severe hemophilia A and B with inhibitors.
Further Reading: Put Option
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Catalyst Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalyst Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.